260
Views
11
CrossRef citations to date
0
Altmetric
Review

Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease

, &
Pages 11-18 | Published online: 15 Jan 2018

Abstract

Severe asthma or therapy-resistant asthma in children is a heterogeneous disease that affects all age-groups. Given its heterogeneity, precision in diagnosis and treatment has become imperative, in order to achieve better outcomes. If one is thus able to identify specific patient phenotypes and endotypes using the appropriate biomarkers, it will assist in providing the patient with more personalized and appropriate treatment. However, there appears to be a huge diagnostic gap in severe asthma, as there is no single test yet that accurately determines disease phenotype. In this paper, we review the published literature on some of these biomarkers and their possible role in bridging this diagnostic gap. We also highlight the cellular and molecular mechanisms involved in severe asthma, in order to show the basis for the novel biomarkers. Some markers useful for monitoring therapy and assessing airway remodeling in the disease are also discussed. A review of the literature was conducted with PubMed to gather baseline data on the subject. The literature search extended to articles published within the last 40 years. Although biomarkers specific to different severe asthma phenotypes have been identified, progress in their utility remains slow, because of several disease mechanisms, the variation of biomarkers at different levels of inflammation, changes in relying on one test over time (eg, from sputum eosinophilia to blood eosinophilia), and the degree of invasive tests required to collect biomarkers, which limits their applicability in clinical settings. In conclusion, several biomarkers remain useful in recognizing various asthma phenotypes. However, due to disease heterogeneity, identification and utilization of ideal and defined biomarkers in severe asthma are still inconclusive. The development of novel serum/sputum-based biomarker panels with enhanced sensitivity and specificity may lead to prompt diagnosis of the disease in the future.

Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

http://youtu.be/t5GOO9IqKqQ

Introduction

Bronchial asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity, reversible airway obstruction, and excessive mucus production that arises from an inappropriate stimulation of the immune system, especially by environmental aeroallergens.Citation1,Citation2 Bronchial asthma more closely resembles a complex of clinical diseases than a single condition. Within the past few years, it has emerged as the most common incommunicable respiratory disease affecting children worldwide.Citation3 Its genetic basis is well established,Citation2 although nongenetic (nonatopic) forms are also recognized, especially in adult subjects.Citation4 Asthma is further distinguished by multiple phenotypes, which may differ based on age of onset, trigger factors, and patterns of severity, as reflected by variably reversible loss of pulmonary function.Citation5

Severe asthma, which occurs in all age-groups, is a clinically and etiologically heterogeneous respiratory disorder that affects about 5%–10% of patients with bronchial asthma.Citation6 It is associated with reduced quality of life, with substantial impact on health-care expenditure.Citation7 Severe asthma refers to “asthma which requires treatment with high-dose inhaled corticosteroids … plus a second controller (and/or systemic corticosteroids) to prevent it from becoming ‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy.”Citation8,Citation9 However, there exists an age-specific variation in the definition of high-dose inhaled corticosteroids (ICSs) for children aged <6 years, 6–12 years, and >12 years.Citation8

Severe asthma, which is now considered a global challenge, consists of multiple phenotypes, such as the inflammatory phenotypes that include severe allergic asthma, eosinophilic asthma, and neutrophilic asthma. This may imply that identifying patients according to phenotypes based on observable clinical characteristics can provide targeted treatment options. Studies are thus beginning to define phenotypic biomarkers, while phenotype-targeted biological therapies are increasingly showing efficacy in the management of severe asthma.Citation8

Given its heterogeneity, precision in diagnosis and treatment has become imperative to achieve a better outcome. If one is thus able to identify specific patient phenotypes and endotypes (biologically distinct groups) using the appropriate biomarkers, it will assist in providing the patient with more personalized and appropriate treatment.

Obviously, there appears to be a huge diagnostic gap in severe asthma, as there is no single test yet that accurately determines disease phenotype. There is also a shift in the value of assessment of one single biomarker to a combination of various markers, considering the heterogeneity of the disease spectrum. Although biomarkers that are specific to different severe asthma phenotypes have been identified, progress in their utility remains slow, because of several disease mechanisms: variation in biomarkers at different levels of inflammation, the change in relying on one test over time (eg, from sputum eosinophilia to blood eosinophilia), and the degree of invasive tests required to collect these biomarkers, which limits their applicability in clinical settings.Citation6,Citation10

This paper reviews the published literature on some of these novel biomarkers and their possible role in bridging the diagnostic gap in severe asthma. The cellular and molecular mechanisms involved in the disease are also highlighted, in order to establish the basis for these markers. Some markers useful for monitoring therapy and assessing airway remodeling in the disease are also discussed.

Literature search: strategy and outcome

In line with the review objectives, a combination of search terms was used to gather articles from the PubMed database between January and July 2017. Articles published within the last 40 years were included. The search terms “severe asthma and biomarkers” yielded 754 publications, “severe asthma phenotypes and biomarkers” gave 231 publications, “severe asthma phenotypes in children and biomarkers” yielded 56, “severe asthma and molecular mechanisms” gave 198, and “severe asthma and cellular mechanisms” yielded 507 publications. However, several studies were either duplicated or failed to meet the review objectives. After exclusion of these publications, 256 articles formed the list from which original and review articles were selected for the current narrative review.

Molecular and cellular mechanisms involved in severe asthma phenotypes

Several published reports have suggested that severe asthma phenotypes are closely linked to genetic factors, age of asthma onset, duration of disease, flare ups, comorbid sinus disease, and inflammatory characteristics.Citation11Citation15 Initial evaluations of patients with asthma using bronchoalveolar lavage and endobronchial biopsies revealed distinct inflammatory subtypes.Citation6 Following the concept of molecular phenotyping, molecular pathways have been linked to clinical and physiological characteristics of the disease.Citation16 Subsequently, molecular and cellular mechanisms have been described for different disease phenotypes. The asthma phenotype was predominantly eosinophilic in children with acute asthma (about 50% of cases), but neutrophilic in adults with acute asthma (about 82%); paucigranulocytic asthma was the most common phenotype in both adults and children with stable asthma.Citation17 Nevertheless, for severe asthma, the recognized inflammatory phenotypes are eosinophilic, noneosinophilic and paucigranulocytic asthma (see ).Citation18 The identification of these phenotypes has propelled the search for novel biomarkers to help in patient classification, targeting therapies, and predicting different mechanisms of disease pathogenesis.Citation19

Table 1 Phenotypes of uncontrolled severe asthma

Studies based on bronchoalveolar lavage and endobronchial biopsies conducted in children have shown that inflammation and remodeling, especially of the epithelium and distal airways, constitute the hallmarks of the pathobiology of severe asthma.Citation20 Characteristically, airway remodeling is associated with local matrix deposition, vascularization, epithelial hyperplasia, and changes in the submucosa, such as hyperplasia of smooth-muscle cells and proliferation of fibroblasts.Citation21

Severe asthma is characterized by neutrophilic inflammation (neutrophilic asthma). This phenotype can occur in both the presence of eosinophilic inflammation or absence of it (severe noneosinophilic asthma with increased neutrophils).Citation18,Citation22 Neutrophilic inflammation is induced by type 2 T-helper (TH2) cells.Citation22,Citation23 Two distinct endotypes are currently recognized – TH2-high (TH2-positive) and TH2-low asthma – based on expression levels of genes encoding IL13, IL5, and IL4, cytokine expression, and responsiveness to ICSs.Citation16 In addition, recruitment of neutrophils can also be mediated by TH17 cells, which have been implicated in asthma pathogenesis, particularly in asthmatics who fail to respond to CS therapy and exhibit airway hyperresponsiveness and decreased posttherapeutic improvement in airflow limitation or forced expiratory volume in 1 second.Citation24,Citation25 In children with the phenotype of severe noneosinophilic asthma characterized by increased neutrophils, neutrophilic inflammation may result from comorbidities, such as bronchiolitis obliterans.Citation18 Other molecular mechanisms that contribute to neutrophil recruitment in the airways and thus neutrophilic airway inflammation include the action of reactive oxygen species,Citation26 the effect of the imbalance between RAGE and its soluble forms,Citation27 and the role of DAM8.Citation28,Citation29

Secondly, severe asthma has also been characterized by eosinophilic recruitment (eosinophilic asthma), and included in the mechanism are mucus plugging and epithelial denudation in the large-airway wall and lumen. It is associated with increased expression of TGFβ and reticular basement membrane (RBM) thickness.Citation11 The RBM is formed by the fusion of alveolar basal lamina and pulmonary capillaries, and constitutes the interface for oxygen and carbon dioxide diffusion. Active recruitment of eosinophils is largely mediated by proteins secreted by the epithelia: the most potent chemoattractant for eosinophils being eotaxin 1 (CCL11), which is responsible for 80% of TGFβ expression in asthma.Citation30Citation32

The other subphenotype (severe paucigranulocytic asthma) has a poorly understood mechanism and is better described for adult populations.Citation33 Its inflammation may be localized to the distal airways only, where it is difficult to obtain biopsy specimens for further analysis. It has been described as having no thickening of the subepithelial BM and lacking the classic inflammation with activation of other cell types.Citation18 Airway remodeling is an important mechanism in severe asthma. The phenotype with fixed airway obstruction resulting from airway remodeling has been highlighted as one of the key features of many severe asthmatics.

In highlighting the role of distal lung inflammation and remodeling in the disease, some investigators have reported that rennin-positive mast cells are increased in the distal airways of patients compared with a normal autopsied distal lung.Citation34 Furthermore, inflammation and remodeling appear to differ between the proximal and distal lung, as another study had reported that fibroblasts (FGF2) from the distal lung proliferated more rapidly at baseline and in response to TGFβ than those from the proximal airway.Citation35 Galectin 3 has been recognized as a marker of airway remodeling, while it is now known that the gene-regulating molecule IRF4 also plays a key role in the development of TH9 lymphocytes, which are mainly implicated in the development of this chronic inflammatory airway disease.Citation36

Research findings have further revealed that the assessment of by-products of oxidative stress is a novel way to monitor disease severity, a concept applicable to severe asthma in terms of biomarkers. Protein–S-glutathionylation is an oxidative modification of reactive cysteines that has emerged as an important player in pathophysiological processes, and it has been shown that genetic ablation of glutaredoxin 1 enhances the resolution of airway hyperresponsiveness and mucus metaplasia in mice with allergic airway disease.Citation37 Glutaredoxin 1/S-glutathionylation redox status in mice has thus been noted as a critical regulator of airway hyperresponsiveness, suggesting that avenues to increase S-glutathionylation of specific target proteins may be beneficial to attenuate airway hyperresponsiveness.Citation38 Monitoring glutaredoxin 1 protein levels in sputum may thus be an important biomarker for assessing therapy in paucigranulocytic severe asthma. Despite myriad potential biomarkers in severe asthma, they can still be grouped as predictors of airway remodeling, epithelium-derived biomarkers, tissue-associated biomarkers, biomarkers of mixed origin (epithelium- and tissue-associated markers), and exhaled breath condensate (EBC), as shown in .

Table 2 Novel biomarkers for diagnostic purposes in severe asthmaTable Footnotea

Novel biomarkers in severe asthma

Reliable markers in severe asthma in children are predicated upon the prospect of using noninvasive and inexpensive methods to obtain and estimate ideal biomarkers for identifying either clinical phenotypes or treatment-response phenotypes, evaluating changes in disease activity, or confirming a diagnosis.Citation6 These biomarkers, which are useful for diagnostic purposes, may be obtained from blood, bronchoalveolar lavage, bronchial biopsies, induced sputum, and EB (eg, such gases as fractional exhaled nitric oxide [FENO] and EBC) (). Induced sputum and EB are noninvasive lower-airway sampling techniques that are easily applicable in children. Gases in EB and other molecules in EBC also stand out as biomarkers of disease. Biomarkers that are found in more easily accessible samples in the pediatric population are summarized in the following sections.

Tissue-associated biomarkers

Basophils, eosinophils, and neutrophils are considered fundamental effector cells that infiltrate the asthmatic airway in conjunction with platelets.Citation39 Sputum neutrophil percentages are highly reproducible in patients with moderate–severe asthma, and can be used to evaluate novel anti-inflammatory therapies; expectedly, targeting neutrophils has been suggested as a therapeutic option for these patients.Citation40,Citation41 Although neutrophilic inflammation has been established as a common occurrence in severe asthma, the use of this specific biomarker in confirming severe asthma is not yet a standard practice, as the functional role of these cells in disease progression remains unclear. Nevertheless, several novel surface biomarkers of neutrophils have been reported as predictors of established disease and airway remodeling (). Some of these surface markers are CD11b, CD62L, CD274,Citation42 CD35,Citation43 CD14, TLR2, TLR4,Citation44 CXCR2, and IL8Rβ.Citation45 Some of the more easily accessible ones have also been highlighted in .

As shown in , eosinophils and their many surface biomarkers have similar roles in severe asthma. They are quite numerous, but a few examples with direct correlation are worthy of note: C3AR,Citation46 CD13,Citation47 CD25,Citation48 CD29,Citation49 CD32,Citation50 CD44/HCAM,Citation51 and galectin 3.Citation52 Similarly, multiple mediators derived from platelets, such as leukotrienes, CXCL4, β-thromboglobulin, CCL5, RANTES, thromboxane, and serotonin, have also been reported as potential markers.Citation49,Citation53Citation56 These mediators are directly correlated with severe asthma, and thus CXCL4 may specifically serve as a disease biomarker for severe asthma.Citation55 Despite the use of eosinophil count in induced sputum as the method of choice to assess eosinophilic lung inflammation (possibly making it a reliable biomarker of airway inflammation),Citation57Citation59 the current recommendation is rather in favor of utilizing blood eosinophils as biomarkers, as this could help to personalize asthma management in patients with severe allergic asthma.Citation6 In fact, some investigators have shown a relationship between blood eosinophil counts (but not sputum eosinophilia) and response to an asthma medication.Citation60 Nevertheless, asthma severity might be linked to a relationship between TGFβ expression and the presence of submucosal eosinophils.Citation6 This is supported by the observation of eosinophilic expression of TGFβ2 isoforms in severe allergic asthma, where this cytokine promotes fibrotic responses and modulates mucin production.Citation61 Other tissue-associated biomarkers that have equally been reported as predictors of disease and airway remodeling are CRP,Citation62 ECP,Citation63 IFNα,Citation64 IFNγ,Citation65 TNFα,Citation66 IL2, IL4, IL18, and IL22.Citation65,Citation67Citation69

Epithelium-derived biomarkers

Again, several studies have reported the potential role of some epithelium-derived biomarkers in severe asthma, especially due to the relative ease of obtaining samples from the respiratory epithelium. Prominent among them are periostin,Citation70,Citation71 fibrinogen,Citation72 MMPs,Citation73Citation76 eotaxins,Citation77 and TIMPsCitation74 (). Specifically, periostin has attracted much scientific interest and elucidation with respect to its role in allergic asthma.Citation78Citation80 It is secreted in bronchial epithelial cells and lung fibroblasts following induction by IL4 and IL13, and its expression is directly related to RBM thickness.Citation81Citation83 Periostin is essentially involved in amplifying and maintaining chronic inflammation arising from allergic diseases,Citation84 as well as initiating the process of subepithelial fibrosis in bronchial asthma.Citation81 Serum periostin, which is a good marker of eosinophilic asthma, is considered a promising biomarker in severe asthma, because of its easy movement from inflamed tissues to blood circulation, making its serum levels a reflection of its local production in lesions induced by TH2-type immunoresponses.Citation85,Citation86 ().

Epithelium- and tissue-associated biomarkers (biomarkers of mixed origin)

Several of these biomarkers have been reported, but the following are highlighted: IL1β,Citation87 osteopontin,Citation88 TGF,Citation89 VEGF,Citation90 and YKL40 (CHI3L1)Citation91 (). Osteopontin is a cytokine, originally described as a structural component of the extracellular matrix, which is capable of binding to proteins and most types of collagen.Citation92 This biomarker is produced by most cells of the immune system, including T cells, B cells, macrophages, neutrophils, eosinophils, natural killer cells, and mast cells, as well as structural cells, including fibroblasts and smooth-muscle and epithelial cells.Citation93 In the study that aimed to estimate osteopontin levels in the serum, bronchoalveolar lavage fluid, and bronchial tissue of healthy controls and asthmatics, serum and bronchoalveolar lavage-fluid levels were significantly elevated in all asthmatics in the steady state, whereas serum levels decreased during exacerbations.Citation88 In addition, osteopontin was upregulated in the bronchial tissue of all patients, and expressed by epithelial, airway, and vascular smooth-muscle cells, myofibroblasts, T lymphocytes, and mast cells, and its expression correlated with RBM thickness and was more prominent in subepithelial inflammatory cells in severe asthma compared to mild–moderate asthma.Citation88

YKL40 is a chitinase-like protein that regulates the formation of collagen fibrils and increases smooth-muscle proliferation.Citation94 It has also been linked with asthma and airway remodeling.Citation95 In fact, some authors have suggested that this biomarker with biological plausibility for airway remodeling (when corrected for genotype) differentiates severe treatment-resistant asthma from controlled persistent asthma and correlates well with other markers for asthma control.Citation91

VEGF is highly expressed in the airway of patients with bronchial asthma, and as it increases airway vascular permeability, the resultant thickening of the airway-wall mucosa may result in narrowing of the airway lumen. This finding has been corroborated by investigators who noted that the VEGF levels in induced sputum were not only increased in asthmatic subjects but were also associated with the degree of airway narrowing and airway vascular permeabilityCitation90 ().

Exhaled breath condensate

EB mainly contains aerosolized, involatile particles of fluid from airway lining, water-vapor condensation, inorganic (O2, N2) and organic (CO2) atmospheric volatile water-soluble gases, and endogenous and exogenous volatile organic compounds.Citation96 EBC is obtained after condensation of EB with a commercially available refrigerating device based on American Thoracic Society/European Respiratory Society guidelines.Citation97 Generally, it has been documented that the following molecules in EBC are elevated in severe asthma: leukotrienes, lipoxins, arachidonic acid metabolites, nitrogen oxides and related products, cytokines, ammonia, oxidative stress markers, hydrogen peroxide, and adenosine.Citation6 Interestingly, few studies that have evaluated and compared its composition in patients with severe asthma and their healthy counterparts show dissimilarities. For example, some authors reported that such eicosanoids as proinflammatory leukotriene LTB4 and anti-inflammatory LXA4 were elevated in asthmatics when compared to healthy subjects, while the LXA4:LTB4 ratio decreased remarkably in EBC in correlation with asthma severity.Citation98 In addition, eotaxin 1 (CCL11) has been evaluated in EBC (among other specimens like blood, sputum and bronchoalveolar lavage fluid) and has been proposed as a tool for assessment of asthma severity.Citation99 Although collection of EBC is a procedure potentially influenced by several endogenous and exogenous factors, its analysis may thus emerge as a promising, safe, and noninvasive method for monitoring severe asthmatics on treatment.Citation97

Fractional exhaled nitric oxide

FENO levels in the respiratory tract are mainly determined by epithelial inducible nitric oxide synthase.Citation100 Measurement of nitric oxide concentration in EB is a quantitative, noninvasive, simple, and safe method to evaluate airway inflammation, to monitor responsiveness to ICS therapy in adults, and to predict asthma-control status in children.Citation101,Citation102 Other studies conducted in adults have also shown that FENO levels correlate more with asthma control than disease severity.Citation103,Citation104 Given the markedly hyperplastic bronchial mucosa, susceptibility of the epithelium to destruction, and flaking and detachment from the RBM seen in severe asthma, FENO levels may be underrepresented.Citation105 Because of this limitation, elevated FENO values are not considered an effective biomarker in the management of severe asthma, but rather as a marker of TH2 inflammation and atopy.Citation8

Conclusion

The identification and utilization of ideal and defined biomarkers in severe asthma remains inconclusive. Apart from disease heterogeneity, the reasons for this include the diverse and overlapping biological aspects of each prospective biomarker, its changing concentrations depending on disease pathobiology, and methods of sample collection/evaluation, as well as the invasiveness of sampling techniques that need specific tools and skills. In children, the challenge of sampling has been circumvented by the use of less invasive methods of sample collection. Therefore, the development of novel serum/sputum-based biomarker panels with enhanced sensitivity and specificity may lead to prompt diagnosis of severe asthma in future.

Acknowledgments

The authors acknowledge the invaluable information obtained from the articles by Chiappori et alCitation6 and Zissler et al.Citation21

Disclosure

The authors report no conflicts of interest in this work.

References

  • MartinezFDVercelliDAsthmaLancet20133821360137224041942
  • BierbaumSHeinzmannAThe genetics of bronchial asthma in childrenRespir Med20071011369137517353123
  • World Health OrganizationAsthma2017 Available from: http://www.who.int/mediacentre/factsheets/fs307/en/index.htmlAccessed March 7, 2017
  • OzdemirCCeyhanBYaziDNon-atopic asthma in children is related to maternal bronchial hyper-reactivityPediatr Allergy Immunol20081924825418397409
  • LemanskeRFBusseWWAsthma: clinical expression and molecular mechanismsJ Allergy Clin Immunol2010125S95S10220176271
  • ChiapporiADe FerrariLFolliCMauriPRiccioAMCanonicaGWBiomarkers and severe asthma: a critical appraisalClin Mol Allergy2015132026430389
  • WalshLJWongCACooperSGuhanARPringleMTattersfieldAEMorbidity from asthma in relation to regular treatment: a community based studyThorax19995429630010092689
  • ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J20144334337324337046
  • American Thoracic SocietyProceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questionsAm J Respir Crit Care Med20001622341235111112161
  • ArronJRIzuharaKAsthma biomarkers: what constitutes a ‘gold standard’?Thorax20157010510725432945
  • HaldarPPavordIDShawDECluster analysis and clinical asthma phenotypesAm J Respir Crit Care Med200817821822418480428
  • MirandaCBusackerABalzarSTrudeauJWenzelSEDistinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammationJ Allergy Clin Immunol200411310110814713914
  • WenzelSEBalzarSAmplefordEIL4Rα mutations are associated with asthma exacerbations and mast cell/IgE expressionAm J Respir Crit Care Med200717557057617170387
  • LiXHowardTDZhengSLGenome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regionsJ Allergy Clin Immunol201012532833520159242
  • HaselkornTZeigerRSChippsBERecent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthmaJ Allergy Clin Immunol200912492192719895984
  • WoodruffPGModrekBChoyDFT-helper type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med200918038839519483109
  • WangFHeXYBainesKJDifferentiating inflammatory phenotypes in adults and children with acute asthmaEur Resp J201138567574
  • CampoPRodríguezFSánchez-GarcíaSPhenotypes and endotypes of uncontrolled severe asthma: new treatmentsJ Investig Allergol Clin Immunol2013237688
  • MooreWCMeyersDAWenzelSEIdentification of asthma phenotypes using cluster analysis in the severe asthma research programAm J Respir Crit Care Med201018131532319892860
  • WenzelSEBusseWWSevere asthma: lessons from the Severe Asthma Research ProgramJ Allerg Clin Immunol20071191421
  • ZisslerUMEsser-von BierenJJakwerthCAChakerAMSchmidt-WeberCBCurrent and future biomarkers in allergic asthmaAllergy20167147549426706728
  • JatakanonAUasufCMaziakWLimSChungKFBarnesPJNeutrophilic inflammation in severe persistent asthmaAm J Respir Crit Care Med19991601532153910556116
  • GibsonPGSimpsonJLSaltosNHeterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8Chest20011191329133611348936
  • SchleimerRPGlucocorticoids suppress inflammation but spare innate immune responses in airway epitheliumProc Am Thorac Soc2004122223016113438
  • BarnesPJAdcockIMGlucocorticoid resistance in inflammatory diseasesLancet20093731905191719482216
  • BoldoghIBacsiAChoudhuryBKDharajiyaNAlamRHazraTKROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammationJ Clin Invest20051152169217916075057
  • SimsGPRoweDCRietdijkSTHerbstRCoyleAJHMGB1 and RAGE in inflammation and cancerAnnu Rev Immunol20102836738820192808
  • Gómez-GaviroMDomínguez-LuisMCanchadoJExpression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin sheddingJ Immunol20071788053806317548643
  • OreoKMGibsonPGSimpsonJLWoodLGMcDonaldVMBainesKJSputum ADAM-8 expression in increased in severe asthma and COPDClin Exp Allergy201344342352
  • ConroyDMWilliamsTJEotaxin and the attraction of eosinophils to the asthmatic lungRespir Res2001215015611686879
  • KimCKKitaHCallawayZThe roles of a Th2 cytokine and CC chemokine in children with stable asthma: potential implication in eosinophil degranulationPediatr Allergy Immunol201021e697e70420444156
  • ZietowskiZTomasiek-LozowskaMMSkiepkoRZietowskaEBodzenta-LukaszykAEotaxin-1 in exhaled breath condensate of stable and unstable asthma patientsRespir Res20101111020704746
  • WenzelSSevere asthma in adultsAm J Resp Crit Care Med200517214916015849323
  • BalzarSChuHWStrandMWenzelSRelationship of small airway chymase-positive mast cells and lung function in severe asthmaAm J Respir Crit Care Med200517143143915563633
  • KotaruCSchoonoverKJTrudeauJBRegional fibroblast heterogeneity in the lung: implications for remodelingAm J Respir Crit Care Med20061731208121516543551
  • StaudtVBothurEKleinMInterferon-regulating factor 4 is essential for the developmental program of T helper 9 cellsImmunity20103319220220674401
  • JiangLDiazPTBestTMStumpfJNHeFZuoLMolecular characterization of redox mechanisms in allergic asthmaAnn Allergy Asthma Immunol201411313714224986036
  • HoffmanSMTullyJELahueKGGenetic ablation of glutaredoxin-1 causes enhanced resolution of airways hyperresponsiveness and mucus metaplasia in mice with allergic airways diseaseAm J Physiol Lung Cell Mol Physiol2012303L528L53822752969
  • IdzkoMPitchfordSPageCRole of platelets in allergic airway inflammationJ Allergy Clin Immunol20151351416142326051948
  • RossallMRCaddenPAMolphySDPlumbJSinghDRepeatability of induced sputum measurements in moderate to severe asthmaRespir Med20141081566156825195138
  • NairPGagaMZervasESafety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trialClin Exp Allergy2012421097110322702508
  • TakTHilveringBTesselaarKKoendermanLSimilar activation state of neutrophils in sputum of asthma patients irrespective of sputum eosinophiliaClin Exp Immunol201518220421226148992
  • MannBSChungKFBlood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapyRespir Res200675916600024
  • SimpsonJLGrissellTVDouwesJScottRJBoyleMJGibsonPGInnate immune activation in neutrophilic asthma and bronchiectasisThorax20076221121816844729
  • NairPGagaMZervasESafety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trialClin Exp Allergy2012421097110322702508
  • KrugNTschernigTErpenbeckVJHohlfeldJMKöhlJComplement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthmaAm J Respir Crit Care Med20011641841184311734433
  • BraunRKFoersterMWorkalemahuGHaefnerDKroegelCWalkerCDifferential regulation of aminopeptidase N (CD13) by transendothelial migration and cytokines on human eosinophilsExp Lung Res200329597712554354
  • BatesMELiuLYEsnaultSExpression of interleukin-5-and granulocyte macrophage-colony-stimulating factor-responsive genes in blood and airway eosinophilsAm J Respir Cell Mol Biol20043073674314630612
  • JohanssonMWHanSTGundersonKABusseWWJarjourNNMosherDFPlatelet activation, P-selectin, and eosinophil β1-integrin activation in asthmaAm J Respir Crit Care Med201218549850722227382
  • KantersDten HoveWLuijkBExpression of activated FcγRII discriminates between multiple granulocyte priming phenotypes in peripheral blood of allergic asthmatic subjectsJ Allergy Clin Immunol20071201073108117697704
  • JohanssonMWActivation states of blood eosinophils in asthmaClin Exp Allergy20144448249824552191
  • GaoPGibsonPGBainesKJAnti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL1βRespir Res201516525616863
  • TornhamreSEhnhageAKölbeckKGEdeniusCLindgrenJAUncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatmentClin Exp Allergy2002321566157312569976
  • ZietkowskiZBodzenta-LukaszykATomasiakMMSkiepkoRMroczkoBSzmitkowskiMChanges in RANTES and β-thromboglobulin after intensive exercise in patients with allergic asthmaInt Arch Allergy Immunol2009148314018716401
  • KnauerKALichtensteinLMAdkinsonNFJrFishJEPlatelet activation during antigen-induced airway reactions in asthmatic subjectsN Engl J Med1981304140414077231463
  • DürkTDuerschmiedDMüllerTProduction of serotonin by tryptophan hydroxylase 1 and release via platelets contribute to allergic airway inflammationAm J Respir Crit Care Med201318747648523328530
  • WadsworthSSinDDorscheidDClinical update on the use of biomarkers of airway inflammation in the management of asthmaJ Asthma Allergy20114778621792321
  • EltboliOBrightlingCEEosinophils as diagnostic tools in chronic lung diseaseExpert Rev Respir Med201373342
  • SzeflerSJWenzelSBrownRAsthma outcomes: biomarkersJ Allergy Clin Immunol2012129923
  • PavordIDKornSHowarthPMepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialLancet201238065165922901886
  • HarropCAGoreRBEvansCMThorntonDJHerrickSETGF-β2 decreases baseline and IL-13-stimulated mucin production by primary human bronchial epithelial cellsExp Lung Res201339394723249391
  • ShimodaTObaseYKishikawaRIwanagaTSerum high-sensitivity C-reactive protein can be an airway inflammation predictor in bronchial asthmaAllergy Asthma Proc201536e23e2825715235
  • KatoMYamadaYMaruyamaKHayashiYSerum eosinophil cationic protein and 27 cytokines/chemokines in acute exacerbation of childhood asthmaInt Arch Allergy Immunol2010152626620523065
  • WrightAKMistryVRichardsonMToll-like receptor 9 dependent interferon-α release is impaired in severe asthma but is not associated with exacerbation frequencyImmunobiology201522085986425662572
  • PenninoDBhavsarPKEffnerRIL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patientsJ Allergy Clin Immunol201313156257023174657
  • ThomasPSHeywoodGEffects of inhaled tumour necrosis factor alpha in subjects with mild asthmaThorax20025777477812200521
  • BoonpiyathadSPornsuriyasakPBuranapraditkunSKlaewsongkramJInterleukin-2 levels in exhaled breath condensates, asthma severity, and asthma control in non-allergic asthmaAllergy Asthma Proc201334e35e4123998235
  • BelliniAMariniMABianchettiLBarczykMSchmidtMMattoliSInterleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patientsMucosal Immunol2012514014922189956
  • RovinaNDimaEBakakosPLow interleukin (IL)-18 levels in sputum supernatants of patients with severe refractory asthmaRespir Med201510958058725840484
  • BoboleaIBarrancoPDel PozoVSputum periostin in patients with different severe asthma phenotypesAllergy20157054054625631525
  • KanemitsuYItoINiimiAOsteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthmaAm J Respir Crit Care Med201419047247425127307
  • DesaiDGuptaSSiddiquiSSputum mediator profiling and relationship to airway wall geometry imaging in severe asthmaRespir Res2013141723398985
  • BoulayMEPrincePDeschesnesFChakirJBouletLPMetalloproteinase-9 in induced sputum correlates with the severity of the late allergen-induced asthmatic responseRespiration20047121622415133340
  • CataldoDDGuedersMMunautCMatrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmaticsLab Invest20048441842414968124
  • HanZXuJZhongNExpression of matrix metalloproteinases MMP-9 within the airways in asthmaRespir Med20039756356712735676
  • KarakocGBYukselenAYilmazMAltintasDUKendirliSGExhaled breath condensate MMP-9 level and its relationship with asthma severity and interleukin-4/10 levels in childrenAnn Allergy Asthma Immunol201210830030422541398
  • IsgroMBianchettiLMariniMABelliniASchmidtMMattoliSThe C-C motif chemokine ligands CCL5, CCL11, and CCL24 induce the migration of circulating fibrocytes from patients with severe asthmaMucosal Immunol2013671872723149666
  • JiaGEricksonRWChoyDFPeriostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patientsJ Allergy Clin Immunol201213064765422857879
  • KanemitsuYMatsumotoHIzuharaKIncreased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroidsJ Allergy Clin Immunol201313230531223791506
  • ParulekarADMustafaAAHananiaNAPeriostin, a novel biomarker of Th2-driven asthmaCurr Opin Pulm Med201420606524247042
  • TakayamaGArimaKKanajiTPeriostin: a novel component of sub-epithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signalsJ Allergy Clin Immunol20061189810416815144
  • SidhuSSYuanSInnesALRoles of epithelial cell-derived periostin in TFG-β activation, collagen production, and collagen gel elasticity in asthmaProc Natl Acad Sci U S A2010107141701417520660732
  • YuyamaNDaviesDEAkaiwaMAnalysis of novel disease-related genes in bronchial asthmaCytokine20021928729612421571
  • ConwaySJIzuharaKKudoYThe role of periostin in tissue remodeling across health and diseaseCell Mol Life Sci2014711279128824146092
  • MasuokaMShiraishiHOhtaSPeriostin promotes chronic allergic inflammation in response to Th2 cytokinesJ Clin Invest20121222590260022684102
  • MatsumotoHSerum periostin: a novel biomarker for asthma managementAllergol Int20146315316024759559
  • BainesKJSimpsonJLWoodLGSputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypesJ Allergy Clin Immunol2014133997100724582314
  • SamitasKZervasEVittorakisSOsteopontin expression and relation to disease severity in human asthmaEur Respir J20113733134120562127
  • TorregoAHewMOatesTSukkarMChungKFExpression and activation of TGF-β isoforms in acute allergen induced remodeling in asthmaThorax20076230731317251317
  • AsaiKKanazawaHKamoiHShiraishiSHirataKYoshikawaJIncreased levels of vascular endothelial growth factor in induced sputum in asthmatic patientsClin Exp Allergy20033359559912752587
  • KonradsenJRJamesANordlundBThe chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthmaJ Allergy Clin Immunol201313232833523628340
  • ButlerWTStructural and functional domains of osteopontinAnn N Y Acad Sci19957606117785926
  • KohAda SilvaAPBansalAKRole of osteopontin in neutrophil functionImmunology200712246647517680800
  • KonradsenJRJamesANordlundBThe chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthmaJ Allergy Clin Immunol201313232833523628340
  • OberCTanZSunYEffect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung functionN Engl J Med20083581682169118403759
  • DentAGSutedjaTGZimmermanPVExhaled breath analysis for lung cancerJ Thorac Dis20135540550
  • HorváthIHuntJBarnesPJExhaled breath condensate: methodological recommendations and unresolved questionsEur Respir J20052652354816135737
  • KazaniSPlanagumaAOnoEBoniniMZahidMMarigowdaGExhaled breath condensate eicosanoid levels associate with asthma and its severityJ Allergy Clin Immunol201313254755323608729
  • WuDZhouJBiHCCL-11 as a potential diagnostic marker for asthma?J Asthma20145184785424796647
  • LaneCKnightDBurgessSEpithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breathThorax20045975776015333851
  • DweikRABoggsPBErzurumSCAn official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applicationsAm J Respir Crit Care Med201118460615
  • YangSParkJLeeYKKimHHahnYSAssociation of longitudinal fractional exhaled nitric oxide measurements with asthma control in atopic childrenRespir Med201510957257925840483
  • GemiciogluBMusellimBDoganIGuvenKFractional exhaled nitric oxide (FeNo) in different asthma phenotypesAllergy Rhinol20145157161
  • SippelJMHoldenWETillesSAExhaled nitric oxide levels correlate with measures of disease control in asthmaJ Allergy Clin Immunol200010664565011031334
  • HamidQGross pathology and histopathology of asthmaJ Allergy Clin Immunol200311143143212589370